Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
1.
Int J Pharm ; 408(1-2): 208-12, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21296135

ABSTRACT

Paclitaxel is an effective and widely used anti-cancer agent. However, the drug is difficult to formulate for parenteral administration because of its low water solubility and Cremophor EL, the expient used for its formulation, has been shown to cause serious side effects. The present study reports an alternative administration vehicle involving a lipophilic paclitaxel prodrug, paclitaxel oleate, incorporated in the core of a nanoparticle-based dosage form. A hydrophobic poly (ß-amino ester) (PbAE) was used to formulate the nanoparticles, which were stabilized with a mixture of phosphatidylcholine, Synperonic® F 108, and poly(ethylene glycol)-dipalmitoyl phosphatidyl ethanolamine. PbAE undergoes rapid dissolution when the pH of the medium is less than 6.5 and is expected to rapidly release its content within the acidic tumor microenvironment and endo/lysosome compartments of cancer cells. PbAE nanoparticles were prepared by an ultrasonication method and characterized for particle size and physical stability. The nanoparticles obtained had a diameter of about 70 nm and a good physical stability when stored at 4 °C. In vitro cellular uptake and release of paclitaxel oleate PbAE nanoparticles were studied in Jurkat acute lymphoblastic leukemia cells. The results were compared with pclitaxel oleate in poly(ɛ-caprolactone) (PCL) particles, that do not display pH-sensitive release behavior, and paclitaxel in PbAE particles. Both uptake and release of the prodrug were faster when administered in PbAE than in PCL, but much slower than those of the free drug in PbAE. Cytotoxicity assay was performed on the formulations at different doses. Paclitaxel and paclitaxel oleate showed almost identical activity, IC50 123 and 128 nM, respectively, while that of the prodrug in PCL was much lower with IC50 at 2.5 µM. Thus, PbAE nanoparticles with the incorporated paclitaxel prodrug paclitaxel oleate may prove useful for replacement of the toxic Cremophor EL and also by improving the distribution of the drug to the tumor.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Drug Carriers/chemistry , Nanoparticles/chemistry , Paclitaxel/administration & dosage , Polymers/chemistry , Prodrugs/administration & dosage , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacokinetics , Cell Survival/drug effects , Chemistry, Pharmaceutical/methods , Dose-Response Relationship, Drug , Humans , Hydrogen-Ion Concentration , Hydrophobic and Hydrophilic Interactions , Jurkat Cells , Paclitaxel/chemistry , Paclitaxel/pharmacokinetics , Particle Size , Prodrugs/chemistry , Prodrugs/pharmacokinetics , Ultrasonics
2.
J Psychiatr Ment Health Nurs ; 16(6): 516-22, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19594673

ABSTRACT

The aim of the study was to explore the relationship between stigmatizing rejection experiences and self-related variables. Our hypothesis was that rejection experiences would be negatively associated with perceptions of self-esteem, empowerment and sense of coherence. A cross-sectional study assessing rejection experiences, empowerment, sense of coherence and self-esteem was performed, including 200 persons in current or earlier contact with mental health services. The results showed that experiences of rejection were negatively associated with sense of coherence, empowerment and self-esteem. This exploratory investigation suggests that experiences of rejection might be a target for coping interventions. Mental health nurses are in a key position to identify patients' experiences of stigma and by that to understand what consequences of devaluation/discrimination can have for the afflicted.


Subject(s)
Interpersonal Relations , Mental Disorders/nursing , Mental Disorders/psychology , Stereotyping , Adaptation, Psychological , Adult , Aged , Aged, 80 and over , Educational Status , Employment/statistics & numerical data , Female , Humans , Male , Middle Aged , Mood Disorders/nursing , Nurse-Patient Relations , Power, Psychological , Psychotic Disorders/nursing , Self Concept , Young Adult
3.
AIDS Care ; 20(3): 273-83, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18351473

ABSTRACT

The primary aim of this study was to test an intervention to support antiretroviral medication adherence among primarily low-income men and women with HIV. The study was a randomized controlled trial (Get Busy Living) with participants assigned to treatment (Motivational Interviewing [MI]) and control groups. Participants were recruited from an HIV/AIDS clinic in Atlanta, Georgia, US. Of those referred to the study, 247 completed a baseline assessment and were enrolled with 125 randomized to the intervention group and 122 to the control group. Participants were patients beginning antiretroviral therapy or changing to a new drug regimen. The intervention consisted of five MI sessions delivered by registered nurses in individual counselling sessions. Participants were paid for each session attended. The intervention sought to build confidence, reduce ambivalence and increase motivation for ART medication-taking. Medication adherence was measured by the Medication Event Monitoring System (MEMS) from the time of screening until the final follow-up conducted approximately 12 months following the baseline assessment. Participants in the intervention condition showed a trend towards having a higher mean percent of prescribed doses taken and a greater percent of doses taken on schedule when compared to the control group during the months following the intervention period. This effect was noted beginning at about the eighth month of the study period and was maintained until the final study month. Although the finding was weaker for overall percent of prescribed doses taken, the results for the percent of doses taken on schedule suggests that the MI intervention may be a useful approach for addressing specific aspects of medication adherence, such as adherrence to a specified dosing schedule.


Subject(s)
Anti-Retroviral Agents/therapeutic use , Directive Counseling/standards , HIV Infections/psychology , Motivation , Patient Compliance/psychology , Treatment Refusal/psychology , Adult , Attitude to Health , Directive Counseling/methods , Female , HIV Infections/drug therapy , Humans , Interviews as Topic , Male , Treatment Outcome , Viral Load
4.
Drug Deliv ; 14(3): 171-5, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17454037

ABSTRACT

The purpose of our research was to evaluate in vitro therapeutic efficacy of doxorubicin (DXR)-loaded immunoliposomes with Fab' fragments of the anti-CD74 antibody LL1 attached to the surface. LL1 is well suited for targeting purposes because it is internalized very fast by B-lymphoma cells. However, at in vivo application whole antibodies show fast clearance in circulation. Taking this fact into consideration, this study was initiated to elucidate the prospects of using Fab' fragments of LL1 in stead of the whole antibody for future targeting in vivo of DXR-loaded liposomes. The Fab' fragments were covalently attached to the surface of sterically stabilized liposomes by use of a PEG-based heterobifunctinal coupling agent. LL1 Fab' conjugated sterically stabilized DXR liposomes showed approximately six times faster accumulation of the drug in Raji human B-lymphoma cells than nontargeted liposomes. In vitro cytotoxicity, quantitated by a tetrazolium assay, against Raji cells gave IC(50) values of 0.13, 0.45, and 0.11 microM for DXR-loaded immunoliposomes, DXR-loaded liposomes and free drug, respectively. The results from this study suggest that DXR-loaded immunoliposomes targeted with Fab' fragments from the anti-CD74 antibody LL1 could be a useful system for future in vivo experiments.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Antigens, Differentiation, B-Lymphocyte/chemistry , Doxorubicin/therapeutic use , Histocompatibility Antigens Class II/chemistry , Immunoglobulin Fab Fragments/pharmacology , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/pharmacology , Cell Line , Cell Survival/drug effects , Doxorubicin/administration & dosage , Doxorubicin/pharmacology , Excipients , Immunochemistry , Immunoglobulin G/chemistry , Kinetics , Liposomes
5.
Eur Phys J E Soft Matter ; 18(1): 105-12, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16184321

ABSTRACT

A newly developed method for determining the frequency-dependent complex Young's modulus was employed to analyze the mechanical response of compacted microcrystalline cellulose, sorbitol, ethyl cellulose and starch for frequencies up to 20 kHz. A Debye-like relaxation was observed in all the studied pharmaceutical excipient materials and a comparison with corresponding dielectric spectroscopy data was made. The location in frequency of the relaxation peak was shown to correlate to the measured tensile strength of the tablets, and the relaxation was interpreted as the vibrational response of the interparticle hydrogen and van der Waals bindings in the tablets. Further, the measured relaxation strength, holding information about the energy loss involved in the relaxation processes, showed that the weakest material in terms of tensile strength, starch, is the material among the four tested ones that is able to absorb the most energy within its structure when exposed to external perturbations inducing vibrations in the studied frequency range. The results indicate that mechanical relaxation analysis performed over relatively broad frequency ranges should be useful for predicting material properties of importance for the functionality of a material in applications such as, e.g., drug delivery, drug storage and handling, and also for clarifying the origin of hitherto unexplained molecular processes.

6.
J Control Release ; 86(1): 93-100, 2003 Jan 09.
Article in English | MEDLINE | ID: mdl-12490375

ABSTRACT

Paclitaxel is one of the most effective and most widely-used anti-cancer agents. However, paclitaxel is difficult to formulate for parenteral administration because of its low aqueous solubility and Cremophor EL, the excipient used for its formulation, has been shown to cause serious side effects. This study reports an alternative administration vehicle involving a lipophilic paclitaxel derivative, paclitaxel oleate, incorporated in the core of a nano-size sterically stabilized oil-in-water (o/w) lipid emulsion. This lipid emulsion, with a particle size of 50 nm, has many favourable properties such as drug-carrier like biocompatibility, physical stability and ease of preparation. When paclitaxel in Cremophor EL/ethanol and paclitaxel oleate in emulsion were incubated with plasma a greater proportion of paclitaxel was found in the lipoprotein pool when formulated as paclitaxel oleate in a lipid emulsion compared to unesterified paclitaxel. The paclitaxel prodrug, paclitaxel oleate, demonstrated cytotoxic activity against cultured HeLa cells and with a marked increase in activity with incubation time. The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively. Pharmacokinetic data, obtained with rabbits, showed significantly greater AUC, higher C(max), lower systemic clearance and lower V(ss) when paclitaxel was formulated as an oleate prodrug in a lipid emulsion than when formulated in Cremophor EL/ethanol. The formulated emulsion may be clinically useful not only for eliminating toxic effects of Cremophor EL but also for improvement of the pharmacokinetic parameters of paclitaxel.


Subject(s)
Fat Emulsions, Intravenous/pharmacokinetics , Paclitaxel/blood , Paclitaxel/pharmacokinetics , Animals , Cell Survival/drug effects , Cell Survival/physiology , Dose-Response Relationship, Drug , Fat Emulsions, Intravenous/chemistry , Female , HeLa Cells/drug effects , HeLa Cells/metabolism , Humans , Paclitaxel/chemistry , Rabbits
7.
Phys Rev Lett ; 89(12): 121801, 2002 Sep 16.
Article in English | MEDLINE | ID: mdl-12225077

ABSTRACT

We study the Dalitz plot of the decay D(+)-->K(-)pi(+)pi(+) with a sample of 15090 events from Fermilab experiment E791. Modeling the decay amplitude as the coherent sum of known Kpi resonances and a uniform nonresonant term, we do not obtain an acceptable fit. If we allow the mass and width of the K(*)(0)(1430) to float, we obtain values consistent with those from PDG but the chi(2) per degree of freedom of the fit is still unsatisfactory. A good fit is found when we allow for the presence of an additional scalar resonance, with mass 797+/-19+/-43 MeV/c(2) and width 410+/-43+/-87 MeV/c(2). The mass and width of the K(*)(0)(1430) become 1459+/-7+/-5 MeV/c(2) and 175+/-12+/-12 MeV/c(2), respectively. Our results provide new information on the scalar sector in hadron spectroscopy.

8.
Phys Rev Lett ; 86(21): 4768-72, 2001 May 21.
Article in English | MEDLINE | ID: mdl-11384344

ABSTRACT

We present the first direct measurements of the pion valence-quark momentum distribution which is related to the square of the pion light-cone wave function. The measurements were carried out using data on diffractive dissociation of 500 GeV/c pi(-) into dijets from a platinum target at Fermilab experiment E791. The results show that the /q&q> light-cone asymptotic wave function describes the data well for Q2 approximately 10 (GeV/c)(2) or more. We also measured the transverse momentum distribution of the diffractive dijets.

9.
Phys Rev Lett ; 86(21): 4773-7, 2001 May 21.
Article in English | MEDLINE | ID: mdl-11384345

ABSTRACT

We have studied the diffractive dissociation into dijets of 500 GeV/c pions scattering coherently from carbon and platinum targets. Extrapolating to asymptotically high energies (where t(min)-->0), we find that when the per-nucleus cross section for this process is parametrized as sigma = sigma0Aalpha, alpha has values near 1.6, the exact result depending on jet transverse momentum. These values are in agreement with those predicted by theoretical calculations of color-transparency.

10.
Phys Rev Lett ; 86(18): 3969-72, 2001 Apr 30.
Article in English | MEDLINE | ID: mdl-11328072

ABSTRACT

We report results of a search for flavor-changing neutral current (FCNC), lepton flavor, and lepton-number violating decays of the D0 (and its antiparticle) into three and four bodies. Using data from Fermilab charm hadroproduction experiment E791, we examine modes with two leptons (muons or electrons) and a rho(0), K( *0), or straight phi vector meson or a nonresonant pi(pi), Kpi, or KK pair of pseudoscalar mesons. No evidence for any of these decays is found. Therefore, we present branching-fraction upper limits at 90% confidence level for the 27 decay modes examined (18 new).

11.
Phys Rev Lett ; 86(5): 765-9, 2001 Jan 29.
Article in English | MEDLINE | ID: mdl-11177935

ABSTRACT

From a sample of 848+/-44 D(+)(s)-->pi(-)pi(+)pi(+) decays, we find gamma(D(+)(s)-->pi(-)pi(+)pi(+))/gamma(D(+)(s)-->straight phipi(+)) = 0.245+/-0.028(+0.019)(-0.012). Using a Dalitz plot analysis of this three body decay, we find significant contributions from the channels rho(0)(770)pi(+), rho(0)(1450)pi(+), f(0)(980)pi(+), f(2)(1270)pi(+), and f(0)(1370)pi(+). We also present the values obtained for masses and widths of the resonances f(0)(980) and f(0)(1370).

12.
Phys Rev Lett ; 86(5): 770-4, 2001 Jan 29.
Article in English | MEDLINE | ID: mdl-11177936

ABSTRACT

From a sample of 1172 +/- 61 D(+)-->pi(-)pi(+)pi(+) decays, we find gamma(D(+)-->pi(-)pi(+)pi(+))/gamma(D(+)-->K-pi(+)pi(+)) = 0.0311 +/- 0.0018(+0.0016)(-0.0026). Using a coherent amplitude analysis to fit the Dalitz plot of these decays, we find strong evidence that a scalar resonance of mass 478(+24)(-23) +/- 17 MeV/c(2) and width 324(+42)(-40) +/- 21 MeV/c(2) accounts for approximately half of all decays.

13.
Int J Pharm ; 205(1-2): 101-8, 2000 Sep 15.
Article in English | MEDLINE | ID: mdl-11000546

ABSTRACT

Administration of doxorubicin (DXR) formulated in sterically stabilized liposomes, (SL) containing engrafted poly(ethylene glycol)-modified phosphatidylethanolamine (PEG-PE) on their surface, has been shown to increase the therapeutic index of the drug. A further improvement could be achieved through targeting of liposome-entrapped drug selectively to cancer cells. This paper describes the conjugation of the anti-B-cell lymphoma monoclonal antibody LL2 to the surface of DXR-loaded liposomes by use of a PEG-based heterobifunctional coupling agent. Competitive-binding ELISA of the resulting immunoliposomes (SIL) against the monoclonal anti-idiotype antibody, WN, indicated preserved immunological activity. The pH-sensitive probe, HPTS was used to study the binding of liposomes with target cells. The results showed a 3.8-fold increased cellular association of SIL compared to that of SL and an apparent internalization of SIL into low pH compartments. Addition of an excess of unconjugated free LL2 displaced about 72% of the HPTS-SIL association with cells. Experiments with 125I-labeled free and SIL-bound LL2 showed approximately 50% degradation for both preparations. In vitro MTT cytotoxicity tests against neoplastic B cells gave IC(50) values of 1.6, 2.9 and 0.35 microM for DXR-SIL, DXR-SL and free DXR, respectively. Leakage of drug from the liposomes apparently reduced the specificity of the cytotoxic action of DXR-SIL.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antineoplastic Agents/administration & dosage , Doxorubicin/administration & dosage , Immunotoxins/administration & dosage , Animals , Antibodies, Monoclonal/pharmacokinetics , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Burkitt Lymphoma/drug therapy , Burkitt Lymphoma/metabolism , Doxorubicin/chemistry , Doxorubicin/pharmacokinetics , Drug Carriers , Immunotoxins/pharmacokinetics , Liposomes , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/metabolism , Mice , Tumor Cells, Cultured
14.
AIDS ; 14(16): 2559-66, 2000 Nov 10.
Article in English | MEDLINE | ID: mdl-11101068

ABSTRACT

OBJECTIVE: To determine the relative contribution of patient non-adherence, provider failure to prescribe prophylaxis, and drug failure to the continued occurrence of Pneumocystis carinii pneumonia (PCP), and to determine correlates of non-adherence. DESIGN: Retrospective case-control study. METHODS: Patients with confirmed or presumptive PCP from May 1995 to September 1997 who had at least 6 months of prior HIV care (cases) were compared to controls matched for initial CD4 cell count and date of initial HIV care. RESULTS: The incidence of PCP declined by 85% in the 28 months of the study. Of the 118 cases of PCP identified, 59 (50%) were in HIV care for > 6 months prior to PCP diagnosis. In a multivariate logistic regression model, risk factors for PCP among patients in HIV care were patient non-adherence [odds ratio (OR), 12.4; 95% confidence interval (CI), 6.4-23.5], use of prophylaxis other than trimethoprim-sulfamethoxazole (OR, 27.0; 95% CI, 13.8-52.9), and absence of antiretroviral use (OR, 7.5; 95% CI, 4.5-12.5). Provider non-adherence occurred in one out of 59 cases (2%), and five out of 106 controls (5%). Of the patients who developed PCP on prophylaxis, 18 cases (30%) appeared due to drug failure; there were no cases of apparent drug failure among patients on trimethoprim-sulfamethoxazole. In multivariate analysis, non-adherence was more common among patients of non-white race, those with a history of injecting drug use, and those with active substance abuse or psychiatric illness. CONCLUSIONS: Patient non-adherence was the most common reason for the occurrence of PCP among patients in HIV care; provider non-adherence was uncommon. Drug failure occurred only among patients on prophylaxis other than trimethoprim-sulfamethoxazole.


Subject(s)
AIDS-Related Opportunistic Infections/prevention & control , Anti-Infective Agents/therapeutic use , Pneumonia, Pneumocystis/epidemiology , Pneumonia, Pneumocystis/prevention & control , Treatment Refusal , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/microbiology , Adult , Case-Control Studies , Chemoprevention , Female , Humans , Male , Multivariate Analysis , Retrospective Studies , Risk Factors , Treatment Failure
15.
J Pharm Pharmacol ; 51(10): 1099-105, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10579680

ABSTRACT

Long-circulating submicron lipid emulsions, stabilized with poly(ethylene glycol)-modified phosphatidylethanolamine (PEG-PE), are promising drug carriers with substantial capacity for solubilization of lipophilic anticancer agents. This study describes the conjugation of the anti-B-cell lymphoma monoclonal antibody LL2 to the surface of lipid-emulsion globules by use of a novel poly(ethylene glycol)-based heterobifunctional coupling agent. The efficiency of coupling of LL2 to the lipid emulsion was 85% (approx.) and essentially independent of the LL2/emulsion particle ratio and amount of surface-bound PEG-PE. Results from sucrose-gradient centrifugation and Sepharose CL-4B gel filtration indicated stable binding of the antibody to the emulsion. The immunoreactivity of the emulsion-LL2 conjugates was tested with alkaline phosphatase-conjugated LL2 against a monoclonal anti-idiotype antibody, WN. The binding of the conjugates to WN increased with increasing surface density of LL2 up to 40 monoclonal antibodies/emulsion particle, and exceeded that for the free monoclonal antibody (approx. 20 molecules/particle). Results from competitive-binding ELISA were indicative of similar displacement curves for free LL2 and emulsion-LL2 conjugates. Direct cellular ELISA revealed similar binding of emulsion-LL2 complexes to three types of Burkitt's lymphoma cell lines, Raji, Ramos and Daudi. The results from this study indicate that emulsion-LL2 complexes might be a useful drug-carrier system for more specific delivery of anticancer drugs to B-cell malignancy.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Lipids , Lymphoma, B-Cell/immunology , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Antibody Affinity , Drug Carriers , Emulsions , Humans , Ligands , Lipids/chemistry , Lymphoma, B-Cell/drug therapy , Phosphatidylethanolamines/chemistry , Polyethylene Glycols/chemistry , Receptors, Cell Surface/metabolism , Tumor Cells, Cultured
16.
Infect Immun ; 67(1): 436-8, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9864251

ABSTRACT

Salmonella typhimurium zwf mutants lacking glucose 6-phosphate dehydrogenase (G6PD) activity have increased susceptibility to reactive oxygen and nitrogen intermediates as well as attenuated virulence in mice. Abrogation of the phagocyte respiratory burst oxidase during experimental infection with zwf mutant Salmonella causes a prompt restoration of virulence, while inhibition of inducible nitric oxide synthase results in delayed lethality. These observations suggest that G6PD-dependent bacterial antioxidant defenses play an important pathogenic role during early salmonellosis and additionally may help to antagonize NO-dependent antimicrobial mechanisms later in the course of infection.


Subject(s)
Glucosephosphate Dehydrogenase/physiology , Nitrogen/metabolism , Reactive Oxygen Species/metabolism , Salmonella typhimurium/enzymology , Salmonella typhimurium/pathogenicity , Animals , Antioxidants/pharmacology , Female , Glucosephosphate Dehydrogenase/metabolism , Glutathione/analogs & derivatives , Glutathione/pharmacology , Hydrogen Peroxide/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitroso Compounds/pharmacology , Phagocytes/drug effects , Phagocytes/metabolism , Phagocytes/microbiology , S-Nitrosoglutathione , Salmonella typhimurium/drug effects , Virulence
17.
Anticancer Drug Des ; 13(5): 453-61, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9702210

ABSTRACT

The DNA topoisomerase I inhibitor camptothecin (CPT) and its analogues are promising anticancer agents with the ability to halt the growth of a range of human tumours. However, the insolubility and instability of the drug in its active lactone from make it very difficult to devise a suitable formulation for clinical testing. This study describes oleic acid esters of the CPT analogues 10-OH-CPT and SN-38, CPT- and SN-38-oleate, which can be intercalated into liposome bilayers and submicron lipid emulsions. The maximum incorporation of drugs was found to be approximately 10 mol% against phospholipid. The novel CPT formulations proved to be very stable against lactone ring opening and were protected from albumin binding. Their in vitro cytotoxic activity against T-47D, Caco 2 and Raji cells was shown to be equal to or higher than that of the parent drugs. Thus the experiments suggest that drug-lipid carrier complexes may be suitable formulations for i.v. and i.m. administration of lipophilic CPT analogues and markedly improve the stability of the active lactone form of the drugs in circulation.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/chemistry , Camptothecin/analogs & derivatives , Camptothecin/chemistry , 1,2-Dipalmitoylphosphatidylcholine , Camptothecin/administration & dosage , Cell Survival/drug effects , Drug Carriers , Emulsions , Humans , Lipid Bilayers , Liposomes , Solubility , Spectrometry, Fluorescence , Tumor Cells, Cultured
18.
Anticancer Drug Des ; 12(6): 503-13, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9311558

ABSTRACT

This study investigated the relevance of combining lipophilic anti-cancer drugs intercalated into the phospholipid bilayer of liposomes. The cytotoxic interaction of two ether lipids, octadecylphosphocholine and ET-18-OCH3, and the chemotherapeutic drugs teniposide and paclitaxel on cancer cells in vitro was evaluated by use of a combined tetrazolium/formazan-labelled thymidine assay. Summation was calculated by the fractional product method. Enhanced cytotoxic activity was found with combinations of the ether lipids with both teniposide and paclitaxel against leukaemic cells. Combination of teniposide and paclitaxel showed antagonism. The benefit of the liposomal formulation form for the ether lipids was supported by the fact that their haemolytic activity was much reduced when they were incorporated into liposomes.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Paclitaxel/pharmacology , Phospholipid Ethers/pharmacology , Phosphorylcholine/analogs & derivatives , Teniposide/pharmacology , Drug Antagonism , Drug Synergism , HL-60 Cells , Hemolysis/drug effects , Humans , Jurkat Cells , Liposomes , Phosphorylcholine/pharmacology
19.
Ophthalmology ; 104(8): 1312-6, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9261319

ABSTRACT

PURPOSE: The purpose of the study is to describe an unusual case of infectious posterior scleritis after excision of a pterygium. METHODS: The case history of a patient in whom anterior and posterior scleritis developed after excision of a pterygium is reviewed. Histopathologic findings are presented. RESULTS: Pathologic examination results of a scleral biopsy site and the eye showed extensive involvement of the posterior sclera with fungi that on culture grew Pseudallescheria boydii. The development of posterior scleral thickening and intrascleral abscesses gave the clinical impression of autoimmune posterior scleritis or possible tumor. Ultrasonography and computed tomography scan of the eye and orbit proved particularly helpful in following progression of scleral involvement. CONCLUSIONS: Pseudallescheria boydii is capable of causing an infectious posterior scleritis, which can mimic autoimmune posterior scleritis. The use of systemic immunosuppressive agents contributed to this unusual clinical presentation. Progression of posterior scleritis in the face of apparent adequate immunosuppressive therapy always should suggest the possibility of tumor or infection.


Subject(s)
Mycetoma , Pseudallescheria , Scleritis/microbiology , Aged , Eye Enucleation , Humans , Immunosuppressive Agents/adverse effects , Male , Mycetoma/diagnosis , Mycetoma/pathology , Mycetoma/therapy , Pterygium/surgery , Sclera/pathology , Scleritis/diagnosis , Scleritis/pathology , Surgical Wound Infection/microbiology , Tomography, X-Ray Computed , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...